ARDX (Ardelyx) Buyback Yield % : 0.00 (As of Apr. 22, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Ardelyx Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Ardelyx's current buyback yield was 0.00%.

Ardelyx Buyback Yield % Historical Data

The historical data trend for Ardelyx's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Buyback Yield % Chart

Ardelyx Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-3.48

-70.63

-12.66

-8.27

Ardelyx Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-8.27	-4.01	-3.28	-	-

Competitive Comparison of Ardelyx's Buyback Yield %

For the Biotechnology subindustry, Ardelyx's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Ardelyx's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Ardelyx Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Ardelyx's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	1206.74112
	=	0.00%

Ardelyx's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	1206.74112
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Ardelyx Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Ardelyx's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

41X:Germany 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Executives

Michael Raab	director, officer: President & CEO	1119 ST PAUL STREET, BALTIMORE MD 21202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Laura A Williams	officer: Chief Medical Officer	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Justin A Renz	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer	officer: See Remarks	78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks	officer: See Remarks	C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
David P. Rosenbaum	officer: Chief Development Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Robert Ora Felsch	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Susan Rodriguez	officer: Chief Commercial Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Jeffrey W Jacobs	officer: VP, Chemistry	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli	officer: See Remarks	C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010